Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07078864
Starting soon Not applicable

The Effect of the Model-Based Care Decision Support System in Pediatric Intensive Care on Nurses' Decision Making and Opinions

NCT07078864 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-06-15
Last updated
2026-05-22

Condition(s) studied

Pediatric Intensive Care Nurses

Investigational drug(s) / intervention(s)

Nursing Care Decision Support System

Nursing Care Decision Support System: Phase Two involves implementing the Nursing Care Decision Support System. Data will be collected using a Descriptive Information Form, the Nurse Decision-Making Scale (pre-test), and a Semi-Structured Interview Form to explore nurses' views. Nurses will receive two training sessions (totaling 4 hours) covering system use, importance, challenges, and solutions. Training will be held in two groups based on shift schedules. A one-week trial will follow, with the researcher answering questions and providing support via a WhatsApp group. Nurses must use the system for at least 15 days (maximum 30 days due to dissertation timeline). Fifteen days after use ends, the Nurse Decision-Making Scale (post-test) and interviews will assess the system's effectiveness and areas for improvement.

Study summary

The Effect of the Model-Based Care Decision Support System in Pediatric Intensive Care on Nurses' Decision Making and Opinions

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Nurses with at least 6 months of experience in intensive care * Nurses actively involved in direct patient care * Nurses who voluntarily agree to participate in the study Exclusion Criteria: * Nurses who are temporarily on leave due to reasons such as maternity leave or unpaid leave

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ankara Üniversity Ankara Turkey (Türkiye)

More Abant Izzet Baysal University trials in Turkey

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07078864 on ClinicalTrials.gov ↗ ← All trials in Turkey